Chad E Paschall, MD | |
3344 N Futrall Dr, Fayetteville, AR 72703-4057 | |
(479) 521-8200 | |
(479) 582-7310 |
Full Name | Chad E Paschall |
---|---|
Gender | Male |
Speciality | Gastroenterology |
Experience | 25 Years |
Location | 3344 N Futrall Dr, Fayetteville, Arkansas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1780627034 | NPI | - | NPPES |
157114001 | Medicaid | AR | |
5N211 | Other | AR | AR BC/BS |
200057640A | Medicaid | OK | |
P00264951 | Other | AR | RR MCR |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RG0100X | Internal Medicine - Gastroenterology | E-4286 (Arkansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Northwest Medical Center-springdale | Springdale, AR | Hospital |
Washington Regional Medical Center | Fayetteville, AR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Texas Digestive Disease Consultants Pllc | 3375531379 | 544 |
News Archive
Researchers in the U.S. have found that amongst the population of smokers who light up to 30 cigarettes a day African Americans and native Hawaiians are at most risk of developing lung cancer.
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
Hundreds of Aboriginal men who became native mounted police in colonial Australia carried a significant burden of responsibility for law and order for white settlers in Queensland and other settlements.
Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.
› Verified 1 days ago
Entity Name | Texas Digestive Disease Consultants Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1508400425 PECOS PAC ID: 3375531379 Enrollment ID: O20191219000304 |
News Archive
Researchers in the U.S. have found that amongst the population of smokers who light up to 30 cigarettes a day African Americans and native Hawaiians are at most risk of developing lung cancer.
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
Hundreds of Aboriginal men who became native mounted police in colonial Australia carried a significant burden of responsibility for law and order for white settlers in Queensland and other settlements.
Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Chad E Paschall, MD Po Box 1523, Fayetteville, AR 72702-1523 Ph: (479) 521-8200 | Chad E Paschall, MD 3344 N Futrall Dr, Fayetteville, AR 72703-4057 Ph: (479) 521-8200 |
News Archive
Researchers in the U.S. have found that amongst the population of smokers who light up to 30 cigarettes a day African Americans and native Hawaiians are at most risk of developing lung cancer.
The ability to form blood vessels is one of evolution's crowning achievements, and something that separates vertebrates (animals with a backbone) from the rest of the animal kingdom.
Hundreds of Aboriginal men who became native mounted police in colonial Australia carried a significant burden of responsibility for law and order for white settlers in Queensland and other settlements.
Silence Therapeutics plc, a leading international RNAi therapeutics company, is pleased to note that its partner, Quark Pharmaceuticals, Inc., has announced the grant of an option to Novartis to obtain an exclusive worldwide license to develop and commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which incorporates Silence's AtuRNAi technology.
› Verified 1 days ago
Lauren Cantwell Paulk, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 1706 E Joyce Blvd Ste 2, Fayetteville, AR 72703 Phone: 479-966-9370 | |
David R Crittenden, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1408 E Elmwood Dr, Fayetteville, AR 72703 Phone: 479-442-0759 | |
Kim R Agee, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 3344 N Futrall Dr, Fayetteville, AR 72703 Phone: 479-521-8200 Fax: 479-582-7310 | |
Dr. David A Churchill, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3211 N Northhills Blvd, Suite 110, Fayetteville, AR 72703 Phone: 479-571-4338 Fax: 479-571-4015 | |
Dr. Marlan Levan Rhame Iii, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1100 N College Ave, Fayetteville, AR 72703 Phone: 479-443-4301 Fax: 479-587-5929 | |
Waqar M Mehal, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 12 E Appleby, Suite 101, Fayetteville, AR 72703 Phone: 479-463-4444 Fax: 479-463-4499 | |
Dr. Juan I Lombeida, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3232 N North Hills Blvd, Fayetteville, AR 72703 Phone: 479-587-1700 |